Evolution of Therapy for Relapsed/Refractory Multiple Myeloma

Author:
Jorge J. Castillo
Search for other papers by Jorge J. Castillo in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 17: Issue 11.5
Online Publication Date:
Nov 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5035
Restricted access

With so many recent advances in relapsed/refractory multiple myeloma, keeping abreast with current treatment recommendations can be challenging. Novel immunomodulators, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, and nuclear export inhibitors have all been added to the armamentarium, and the choice of which of these drugs or drug combinations to use depends on individual disease-related and patient-related factors, previous therapies, and treatment toxicities. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jorge J. Castillo provided an overview of the myriad treatments available for patients with relapsed/refractory multiple myeloma, as well as therapies on the horizon.

Disclosures: Dr. Castillo has disclosed that he receives grant/research support and consulting fees from BeiGene, Janssen Pharmaceutical Products, LP, and Pharmacyclics; and that he receives grant/research support from AbbVie, Inc., and TG Therapeutics, Inc.

Correspondence: Jorge J. Castillo, MD, Dana-Farber Cancer Institute, 450 Brookline Avenue, M221, Boston, MA 02215. Email: jorgej_castillo@dfci.harvard.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142–152.

  • 2.

    Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374:1621–1634.

  • 3.

    Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319–1331.

  • 4.

    Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373:621–631.

  • 5.

    Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016;17:27–38.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754–766.

  • 7.

    Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:781–794.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:1811–1822.

  • 9.

    Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130:974–981.

  • 10.

    Rosenbaum CA, Stephens LA, Kukreti V, et al. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): a Multiple Myeloma Research Consortium multicenter study [abstract]. J Clin Oncol 2016;34:Abstract 8007.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    San-Miguel JF, Hungria VT, Yoon SS et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15:1195–1206.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant 2015;21:2039–2051.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
4
Article Category:
Research Article
Print Publication Date:
01 Nov 2019
Online Publication Date:
Nov 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4754 2132 576
PDF Downloads 1617 155 38
EPUB Downloads 0 0 0